Original language | English |
---|---|
Pages (from-to) | 452-454 |
Number of pages | 3 |
Journal | Canadian Journal of Ophthalmology |
Volume | 55 |
Issue number | 5 |
DOIs | |
Publication status | Published - Oct 2020 |
Bibliographical note
Funding Information:Dr. Varun Chaudhary has investigator-sponsored research grants and participates in clinical trials funded by Novartis, Bayer, and Allergan; Dr. Chaudhary has also served on the advisory board and is consultant for Novartis and Bayer. Dr. Cynthia Qian has served as consultant for Novartis, Bayer, Allergan, and Bausch and Lomb. Dr. Alan Berger serves as consultant and receives honoraria from Novartis, Bayer, Allergan, and Roche. Dr. James Whelan has received honoraria from Alcon, Novartis, and Bayer, and has investigator-sponsored research grants from Novartis. Dr. Amin Kherani participates in clinical trials funded by Novartis, Bayer, Allergan, Alcon, and Bausch and Lomb. Dr. Arif Samad participates in clinical trials funded by, and is consultant with, Novartis and Bayer. Dr. Jason Noble serves on the advisory board of Novartis and Bayer, and is a speaker for Novartis. None of these have any bearing on the current study. The remaining authors have no financial disclosures to declare. This research did not receive any funding or grants from agencies in the public, commercial, or not-for-profit sectors.
Funding Information:
?, Dr. Varun Chaudhary has investigator-sponsored research grants and participates in clinical trials funded by Novartis, Bayer, and Allergan; Dr. Chaudhary has also served on the advisory board and is consultant for Novartis and Bayer. Dr. Cynthia Qian has served as consultant for Novartis, Bayer, Allergan, and Bausch and Lomb. Dr. Alan Berger serves as consultant and receives honoraria from Novartis, Bayer, Allergan, and Roche. Dr. James Whelan has received honoraria from Alcon, Novartis, and Bayer, and has investigator-sponsored research grants from Novartis. Dr. Amin Kherani participates in clinical trials funded by Novartis, Bayer, Allergan, Alcon, and Bausch and Lomb. Dr. Arif Samad participates in clinical trials funded by, and is consultant with, Novartis and Bayer. Dr. Jason Noble serves on the advisory board of Novartis and Bayer, and is a speaker for Novartis. None of these have any bearing on the current study. The remaining authors have no financial disclosures to declare. This research did not receive any funding or grants from agencies in the public, commercial, or not-for-profit sectors.
ASJC Scopus Subject Areas
- Ophthalmology